Again, there are no big changes for stock classification. Picked biotech stocks are categorized into several groups: I) short-term investment (this will include biotech scams that can be pumped in nearest future); II) biotech gems that have strong science basis and pps below $15, potential buyouts targets for Big Pharmas; III) big cap biotechs for long-term investment (3 and more years)I.
1) SAVA (buy it now, take a profit and then short before Dec 10 to get a huge profit after this biotech scam will fail - Phase 3 for Alzheimer's disease will show that drug was a fake
2) QNCX (will grow on promising clinical results)
3) ROIV (good cash position, promising clinical trials results)
4) THRD (good recovery after a drop)
II.
1) IOVA
2) ALLO
3) ACET
4) ARTV
5) NTLA
6) QNCX
III.
1) NVO
2) NTRA
3) EXAS
4) EXEL
5) GH
6) TWST
7) APGE
to be continued...
I will avoid in 2024:
1) SAVA (scam, will fail very soon in 2024, you can short at high)
2) XOMA
3) NVCR
4) SRPT